- LXRP’s
DehydraTECH has been shown to outperform conventional cannabis
formulations and deliver 475 percent more CBD to the bloodstream in the
first 15 minutes
- Compared
to other industry formulations, DehydraTECH delivered cannabinoids quicker
at industry-leading volumes
- A
DehydraTECH formulation achieved a 319 percent higher CBD blood
concentration level at 60 minutes than the generic coconut oil formulation
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented
DehydraTECH delivery technology has demonstrated in animal lab tests that it
can deliver cannabinoids to the bloodstream more quickly than conventional
cannabinoid formulations (http://ibn.fm/pYSzq).
At 15 minutes into the test, the DehydraTECH formulation achieved a blood
concentration level that was 475 percent higher than a generic coconut oil
formulation; at 60 minutes, the blood concentration level was 319 percent
higher.
Lab tests and actual licensed use in the cannabis industry
have proved that DehydraTECH’s long-chain fatty acid (“LCFA”) formulation is
able to deliver cannabinoids faster than formulations with medium-chain
triglyceride (“MCT”) oils, such as coconut oil. DehydraTECH also offers the
most advanced flavor and aroma-profile masking techniques in the industry. The
groundbreaking technology could negate the need for artificial chemical masking
agents or flavoring agents/sweeteners that mask the bitter flavors and aromas
of cannabis.
Over the entire 60 minutes of the study, the DehydraTECH
LCFA formulation delivered a CBD blood concentration level that was 334 percent
higher than the level identified in animals that received the MCT oil
formulation. The lab tests on animals compared how quickly a DehydraTECH
formulation containing LCFA could deliver cannabinoids to the bloodstream, as
compared to a concentration-matched conventional industry cannabinoid edible
formulation with MCT oil. Coconut oil is commonly used due to its luxurious
taste and mouth-feel, which can hide unpleasant cannabis flavors.
The result is that, in the head-to-head animal absorption
study, the coconut oil formulations delivered cannabinoids into animal
bloodstreams poorly, at about one-fourth the rate of the patented Lexaria LCFA.
The DehydraTECH formulation was shown to deliver CBD more quickly than MCT oil
formulations to the 10 male Sprague-Dawley rats tested.
Not only is delivery to the bloodstream enhanced; eight
hours into the study, brain tissue was sampled to quantify CBD delivery into
the brain. The DehydraTECH-enabled formulation outperformed the MCT oil
formulation by 246 percent. First discovered in two series of nicotine
absorption tests in animals conducted in 2018, LXRP’s DehydraTECH continued to
deliver a drug, both to the bloodstream and across the blood-brain barrier,
more effectively than industry standards. As a result, the efficient delivery
could mean increased consumer satisfaction and utilization of lower dosage
quantities.
LXRP is a bioscience company with North American operations
and a drug-delivery platform innovator. LXRP’s disruptive delivery technology,
DeydraTECH, is out-licensed by the company. The technology is designed to
promote healthier ingestion methods and lower overall dosing. LXRP is the only
company globally to have a patent issued for the oral delivery of all
cannabinoids. DehydraTECH has received patents in the United States and
Australia, and it has multiple patents pending in more than 40 countries
worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
